Since biomarker testing was mostly relevant for patients considered for anti-EGFR therapy (KRAS, NRAS) or younger patients (MMR testing for Lynch syndrome or BRAF testing for prognostication), it is possible that more young and fit patients with mCRC were tested. The gene discussed is NRAS; the disease is Lynch syndrome.